Physiologically-based pharmacokinetic model for evaluating gender-specific exposures of N-nitrosodimethylamine (NDMA)

被引:3
|
作者
Kang, Dong Wook [1 ]
Kim, Ju Hee [1 ]
Choi, Go-Wun [1 ]
Cho, Seok-jin [1 ]
Cho, Hea-Young [1 ]
机构
[1] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea
关键词
N-nitrosodimethylamine (NDMA); Physiologically-based pharmacokinetic (PBPK) model; Toxicokinetics; Tissue distribution; Monte Carlo simulation; CHRONIC INGESTION; INBRED RATS; LIVER; NITROSODIETHYLAMINE; METABOLISM; DIMETHYLNITROSAMINE; CARCINOGENESIS; MICE; AGE;
D O I
10.1007/s00204-023-03652-8
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
N-nitrosodimethylamine (NDMA) is classified as a human carcinogen and could be produced by both natural and industrial processes. Although its toxicity and histopathology have been well-studied in animal species, there is insufficient data on the blood and tissue exposures that can be correlated with the toxicity of NDMA. The purpose of this study was to evaluate gender-specific pharmacokinetics/toxicokinetics (PKs/TKs), tissue distribution, and excretion after the oral administration of three different doses of NDMA in rats using a physiologically-based pharmacokinetic (PBPK) model. The major target tissues for developing the PBPK model and evaluating dose metrics of NDMA included blood, gastrointestinal (GI) tract, liver, kidney, lung, heart, and brain. The predictive performance of the model was validated using sensitivity analysis, (average) fold error, and visual inspection of observations versus predictions. Then, a Monte Carlo simulation was performed to describe the magnitudes of inter-individual variability and uncertainty of the single model predictions. The developed PBPK model was applied for the exposure simulation of daily oral NDMA to estimate blood concentration ranges affecting health effects following acute-duration (<= 14 days), intermediate-duration (15-364 days), and chronic-duration (>= 365 days) intakes. The results of the study could be used as a scientific basis for interpreting the correlation between in vivo exposures and toxicological effects of NDMA.
引用
收藏
页码:821 / 835
页数:15
相关论文
共 50 条
  • [21] Physiologically-based pharmacokinetic (PBPK) model to describe the disposition of pyronaridine
    Diep, John K.
    Lingerfelt, Mary A.
    Ekins, Sean
    Rao, Gauri G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S34 - S34
  • [22] Physiologically-based pharmacokinetic modeling of nilotinib to determine serum, cerebrospinal fluid, and brain exposures
    Venuto, C.
    Simuni, T.
    Fiske, B.
    Coffey, C.
    Matthews, H.
    Wyse, R.
    Brundin, P.
    Simon, D.
    Schwarzschild, M.
    Weiner, D.
    Adams, J.
    Trusso, L.
    Kostrzebski, M.
    Ward, T.
    Rafaloff, G.
    Merchant, K.
    MOVEMENT DISORDERS, 2020, 35 : S486 - S486
  • [23] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PB-PK) MODEL FOR DESETHYLAMIODARONE
    HOU, ZY
    BALTER, NJ
    WOOSLEY, RL
    SCHWARTZ, SL
    CIRCULATION, 1990, 82 (04) : 196 - 196
  • [24] Physiologically-based pharmacokinetic model for 2,4-dinitrophenol
    Lyndsey F. Meyer
    Pooja M. Rajadhyaksha
    Dhaval K. Shah
    Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49 : 325 - 336
  • [25] Development and application of a physiologically-based pharmacokinetic model for ractopamine in goats
    Ai, Jing
    Gao, Yunfeng
    Yang, Fan
    Zhao, Zhen
    Dong, Jin
    Wang, Jing
    Fu, Shiyi
    Ma, Ying
    Gu, Xu
    FRONTIERS IN VETERINARY SCIENCE, 2024, 11
  • [26] Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia
    Lee, Joomi
    Kim, Min-Gul
    Jeong, Hyeon-Cheol
    Shin, Kwang-Hee
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2021, 29 (01) : 33 - 44
  • [27] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR THE INHIBITION OF ACETYLCHOLINESTERASE BY ORGANOPHOSPHATE ESTERS
    GEARHART, JM
    JEPSON, GW
    CLEWELL, HJ
    ANDERSEN, ME
    CONOLLY, RB
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 : 51 - 60
  • [28] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY
    Kyler, K.
    Shakhnovich, V.
    Selvarangan, R.
    Sasidharan, A.
    Chan, S.
    Artz, N.
    Williams, V.
    Friesen, C.
    Pearce, R.
    Gaedigk, A.
    Leeder, J.
    Galetin, A.
    Johnson, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S107
  • [29] Physiologically-based pharmacokinetic model for 2,4-dinitrophenol
    Meyer, Lyndsey F.
    Rajadhyaksha, Pooja M.
    Shah, Dhaval K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (03) : 325 - 336
  • [30] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR ABSORPTION OF ORAL PARACETAMOL IN MAN
    CLEMENTS, JA
    NIMMO, WS
    HEADING, RC
    PRESCOTT, LF
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1978, 30 : P60 - P60